NASDAQ · GNLX
Genelux Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GNLX: Nov 4, 2026
Genelux Corporation Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.21.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.19 | $-0.21 | 2 |
| Dec 2026 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Jun 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Quiver Quantitative · Zacks- RTTNews · Sep 8, 12:11 AM EDTISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision(RTTNews) – The biotech and pharma stocks to watch on Tuesday include iSpecimen, which gained more than 37% in overnight trading on Monday despite no specific news; Genelux, with a key clinical catalyst for its lead candidate Olvi-Vec expected in the coming months; Anixa Bioscien
- RTTNews · Jan 9, 7:53 AM ESTWeekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances(RTTNews) – The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.
- RTTNews · Jan 5, 9:23 PM ESTAfter-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains(RTTNews) – Several biotechnology and pharmaceutical names posted notable gains in after-hours trading on Monday, driven by clinical trial updates, regulatory progress, and investor anticipation ahead of key data releases.
- RTTNews · Jan 5, 9:59 AM ESTGenelux Reports Durable Responses In Systemic Olvi-Vec Lung Cancer Trials(RTTNews) – Genelux Corporation (GNLX) today announced encouraging interim data showing partial responses of up to 85% tumor shrinkage in platinum-relapsed small cell lung cancer patients treated with systemically administered Olvi-Vec immunochemotherapy.
- RTTNews · Jan 5, 9:03 AM ESTGenelux Reports Positive Interim Results From Olvi-Vec Lung Cancer Trials(RTTNews) – Genelux Corporation (GNLX) on Monday reported interim results from two ongoing trials evaluating Olvi-Vec in patients with progressive lung cancer: a Phase 1b/2 study in small cell lung cancer (SCLC) and a Phase 2 VIRO-25 study in non-small cell lung cancer (NSCLC).
- RTTNews · Jan 2, 8:19 AM ESTGenelux Corp Appoints Jason Litten CMO(RTTNews) – Genelux Corp. (GNLX), a clinical-stage immuno-oncology company, Friday announced that it has appointed Jason Litten as Chief Medical Officer, effective January 2.
- Fintel · Oct 21, 8:04 PM EDTLake Street Initiates Coverage of Genelux (GNLX) with Buy RecommendationFintel reports that on October 21, 2025, Lake Street initiated coverage of Genelux (NasdaqCM:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 204.02% Upside
- RTTNews · Sep 11, 12:32 AM EDTAfter-Hours Biotech Gainers: Insider Buys, Trial Updates, And Strategic Deals Fuel Momentum(RTTNews) – Biotech stocks are showing renewed momentum, with several small-cap names posting notable after-hours gains and attracting investor attention. From insider buying and strategic partnerships to clinical trial progress and bold financial moves, companies like Nautilus B
- Quiver Quantitative · Jul 21, 2:20 PM EDTNew Analyst Forecast: $GNLX Given $10.0 Price TargetWe just received data on a new analyst forecast for $GNLX. Christopher Liu from LUCID CAPITAL MARKETS set a price target of 10.0 for GNLX.
- Quiver Quantitative · Jul 7, 7:13 AM EDTGenelux Corporation Appoints Eric Groen as General Counsel and Head of Business DevelopmentGenelux Corporation appointed Eric Groen as General Counsel and Chief Compliance Officer, enhancing its executive team for growth.
- Zacks · Jun 2, 12:00 PM EDTGenelux Corporation (GNLX) Upgraded to Buy: Here's What You Should KnowGenelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Apr 18, 9:40 AM EDTIs EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?Here is how EUROFINS SCIENT (ERFSF) and Genelux Corporation (GNLX) have performed compared to their sector so far this year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Genelux Corporation from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.